Clinical Features of Cutaneous Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cells Transplantation in Children with Hemato-Oncological Diseases

The graft-versus-host disease (GvHD) is frequent complication, it occurs in 50% of patients after allogeneic hematopoietic stem cell transplantation (HSCT) and it is one of the major causes of mortality not associated with disease recurrence. Skin lesion in the symptom complex of acute GvHD develops within the first 100 days after HSCT, and it is complicated diagnostic and therapeutic problem. Significant immunosuppressive status of children during the posttransplant period enhances and changes the course of dermatoses, infections, drug toxicity. Finally, it can lead to immunoallergic processes with possible development to generalized life-threatening diseases of the skin and mucous membranes. Meanwhile, toxic, allergic and infectious skin lesions can be present simultaneously or develop sequentially. The description of the clinical picture of skin lesions in acute GvHD is really crucial and has scientific and practical significance due to relatively small frequency of HSCT in children with oncology diseases. The article summarizes data on etiology, pathogenesis, clinical forms, diagnostic and treatment methods of cutaneous complications of the early post-transplantation period after HSCT.

1. Rumyantsev AG, Maschan AA, Balashov DN, Skvortsova YuV. Federal’nye klinicheskie rekomendatsii po lecheniyu khronicheskoi reaktsii “Transplantat protiv khozyaina” posle transplantatsii gemopoeticheskikh stvolovykh kletok u detei. Moscow; 2015. (In Russ). Av. at: http://nodgo.org/sites/default/files/29.%20%28%D0%93%29%D1%85%D1%80%20%20%D1%82%D0%B3%D1%81%D0%BA%D0%A0.pdf. Link active on 15.10.2020.

2. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956. doi: 10.1016/j.bbmt.2005.09.004.

3. Sung AD, Chao NJ. Acute graft-versus-host disease: are we close to bringing the bench to the bedside? Best Pract Res Clin Haematol. 2013;26(3):285–292. doi: 10.1016/j.beha.2013.10.009.

4. Hematopoietic Stem Cell Transplantation and Cellular Therapies. The EBMT Handbook. Carreras E, Dufour C, Mohty M Kröger N, eds. Springer; 2019. 688 р. doi: 10.1007/978-3-030-02278-5.

5. Paun O, Phillips T, Fu P, et al. Cutaneous complications in hematopoietic cell transplant recipients: impact of biopsy on patient management. Biol Blood Marrow Transplant. 2013;19(8): 1204–1209. doi: 10.1016/j.bbmt.2013.05.006.

6. Ayuk F, Savani BN. Skin, Hair and Musculoskeletal Complications. In: Hematopoietic Stem Cell Transplantation and Cellular Therapies. The EBMT Handbook. Carreras E, Dufour C, Mohty M Kröger N, eds. Springer; 2019. pp. 409–413. doi:10.1007/978-3-030-02278-5_54.

7. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015; 21(3):389–401.e1. doi: 10.1016/j.bbmt.2014.12.001.

8. Pidala J, Vogelsang G, Martin P, et al. Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica. 2012;97(3):451–458. doi: 10.3324/haematol.2011.055186.

9. Saliba RM, de Lima M, Giralt S, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007;109(7): 2751–2758. doi: 10.1182/blood-2006-07-034348.

10. Zeiser R, Penack O, Holler E, Idzko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med (Berl). 2011;89(9):833–845. doi: 10.1007/s00109-011-0767-x.

11. Harris AC, Young R, Devine S, et al. International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10. doi: 10.1016/j.bbmt.2015.09.001.

12. Ion D, Stevenson K, Woo SB, et al. Characterization of oral involvement in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(11):1717–1721. doi: 10.1016/j.bbmt.2014.06.031.

13. Surjana D, Robertson I, Kennedy G, et al. Acute cutaneous graft-versus-host disease resembling type II (atypical adult) pityriasis rubra pilaris. Australas J Dermatol. 2015;56(1):e21–e23. doi: 10.1111/ajd.12108.

14. Huang J, Pol-Rodriguez M, Silvers D, Garzon MC. Acquired ichthyosis as a manifestation of acute cutaneous graft-versushost disease. Pediatr Dermatol. 2007;24(1):49–52. doi: 10.1111/j.1525-1470.2007.00333.x.

15. Matsushita T, Hasegawa M, Shirasaki F, et al. A case of acute cutaneous graft-versus-host disease mimicking psoriasis vulgaris. Dermatology. 2008;216(1):64–67. doi: 10.1159/000109361.

16. Betts BC, Young JA, Ustun C, et al. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? Biol Blood Marrow Transplant. 2011;17:1562–1568. doi: 10.1016/j.bbmt.2011.04.004.

17. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3): 524–529. doi: 10.1016/j.jaad.2008.05.018.

18. Hu SW, Cotliar J. Acute graft-versus-host disease following hematopoietic stem-cell transplantation. Dermatol Ther. 2011; 24(4):411–423. doi: 10.1111/j.1529-8019.2011.01436.x.

19. Ruiz-Genao DP, GF-Villalta MJ, Penas PF, et al. Pustular acral erythema in a patient with acute graft-versus-host disease. J Eur Acad Dermatol Venereol. 2003;17(5):550–553. doi: 10.1046/j.1468-3083.2003.00801.x.

20. Horn TD, Beveridge RA, Egorin MJ, et al. Observations and proposed mechanism of N,N’,N’’-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation. Arch Dermatol. 1989; 125:524–527.

21. Callen J, Jorizzo J, Bolognia J, et al. Dermatological Signs of Internal Disease. 4th Ed. Saunders; 2009. р. 323.

22. Mays SR, Kunishige JH, Truong E, et al. Approach to the morbilliform eruption in the hematopoietic transplant patient. Semin Cutan Med Surg. 2007;26(3):155–162. doi: 10.1016/j.sder.2007.09.004.

23. Peñas PF, Zaman S. Many faces of graft-versus-host disease. Australas J Dermatol. 2010;51(1):1–10. doi: 10.1111/j.1440-0960.2009.00577.x.

24. Byun HJ, Yang JI, Kim BK, Cho KH. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. J Am Acad Dermatol. 2011;65(4):726–732. doi: 10.1016/j.jaad.2010.07.042.

25. Hillen U, Hausermann P, Massi D, et al. Consensus on per forming skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutaneous graft-versus-host disease. J Eur Acad Dermatol Venereol. 2015; 29(5):948–954. doi: 10.1111/jdv.12737.

26. Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157–e167. doi: 10.1016/S2352-3026(19)30256-X.

27. Manalo IF, Miller IA, Davies LS. More immune dysregulation: sarcoidosis and chronic graft-versus-host disease after allogeneic stem cell transplant. JAAD Case Rep. 2016;2(2):138–140. doi: 10.1016/j.jdcr.2016.01.008.

28. Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft versus host disease of the skin. Sci Transl Med. 2010;2(13): 1–19. doi: 10.1126/scitranslmed.3000406.

29. Levine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2(1):21–29. doi: 10.1016/S2352-3026(14)00035-0.

30. Pidala J, Sigdel TK, Wang A, et al. A combined biomarker and clinical panel for chronic graft versus host disease diagnosis. J Pathol Clin Res. 2017;3(1):3–16. doi: 10.1002/cjp2.58.